<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amy McMichael, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maria Hordinsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H109567509">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Female pattern hair loss (FPHL) is a common form of nonscarring hair loss that primarily occurs in adult females. The condition is characterized by the progressive loss of terminal hairs over the frontal and vertex regions of the scalp, resulting in a visible reduction in hair density  (
         <a class="graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195" href="/z/d/graphic/87193.html" rel="external">
          picture 1A-C
         </a>
         ). Unlike many cases of androgenetic alopecia in males (male pattern hair loss), the loss of terminal hairs in affected areas is usually incomplete, and the frontal hairline is often spared.
        </p>
        <p>
         The pathogenesis, clinical manifestations, and diagnosis of FPHL will be reviewed here. Other forms of nonscarring hair loss and the treatment of FPHL are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">
          "Alopecia areata: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">
          "Alopecia related to systemic cancer therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15683.html" rel="external">
          "Telogen effluvium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99226.html" rel="external">
          "Traction alopecia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86648.html" rel="external">
          "Female pattern hair loss (androgenetic alopecia in females): Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H516820567">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, the term "androgenetic alopecia" was the primary term used to refer to the appearance of the common, progressive loss of terminal hair on the frontal scalp and/or vertex of the scalp regardless of the patient's sex. The term "andro" signified a hormonal etiology and "genetic" signified a contribution of heredity to the clinical phenotype.
        </p>
        <p>
         Over the years, as more work on hair loss was published, "female pattern hair loss" became the preferred term for this form of hair loss in females. This newer terminology helps to distinguish the different clinical features of this process in females versus males and reflects the lack of evidence to support a hormonal contribution in all cases of the condition.
        </p>
        <p>
         Further, some authors use the terms "androgen-dependent FPHL" and "androgen-independent FPHL" to separate patients with FPHL due to androgen excess from patients with FPHL and normal androgen levels [
         <a href="#rid1">
          1
         </a>
         ]. The term "female pattern alopecia" has also been used in place of FPHL.
        </p>
        <p class="headingAnchor" id="H109567516">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         FPHL is a common condition, although the prevalence may vary in different populations. Studies from the United States, England, and Australia have reported prevalences higher than studies from South Africa, China, South Korea, and Taiwan; however, limitations of the available data preclude definitive conclusions on the relative prevalence of FPHL in different populations [
         <a href="#rid2">
          2-4
         </a>
         ]. Examples of studies reporting prevalence include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A community-based study in China that assessed 8446 women found FPHL in 6 percent [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A South African study that assessed 597 Black women identified FPHL in 4 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A United States study that assessed 1006 White women found FPHL in 19 percent [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although FPHL can occur at any time in life beginning in childhood, the condition most commonly occurs following menopause [
         <a href="#rid7">
          7-9
         </a>
         ]. The age-related rise in FPHL was clearly demonstrated in the American series mentioned above; FPHL was detected in only 4 of 121 women between the ages of 20 and 29 (3 percent), but in 41 of 140 women between ages 70 and 89 (29 percent) [
         <a href="#rid6">
          6
         </a>
         ]. In a British study of 377 women who presented to a general dermatology clinic with concerns unrelated to hair loss, 38 percent of women over the age of 70 years had FPHL [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H109567523">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The visible thinning of hair over the frontal scalp and vertex of the scalp in FPHL results from a progressive decrease in the ratio of terminal hairs to shorter, thinner vellus hairs in the affected areas, a process known as follicular miniaturization [
         <a href="#rid11">
          11
         </a>
         ]. As part of this process, the duration of the anagen (growth) phase of hair follicles shortens from a normal duration of a few years to only weeks to months [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The mechanism through which follicular transformation occurs in FPHL is not completely understood. Although the crucial roles of androgens and genetic susceptibility in male androgenetic alopecia are well accepted, the degree to which these factors contribute to FPHL in most patients is less clear. (See
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432607103">
         <span class="h2">
          Androgens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Male androgenetic alopecia occurs as a consequence of the effects of dihydrotestosterone (a potent metabolite of testosterone) on susceptible hair follicles. Dihydrotestosterone binds to androgen receptors in hair follicles, resulting in the upregulation of genes responsible for the gradual transformation of terminal hair follicles to miniaturized hair follicles. The pattern of the hair loss, which typically spares the occipital scalp, reflects regional differences in the sensitivity of scalp follicles to androgens  (
         <a class="graphic graphic_picture graphicRef83805" href="/z/d/graphic/83805.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Androgens'
         </a>
         .)
        </p>
        <p>
         Some authors have theorized that a similar process contributes to the development of FPHL [
         <a href="#rid13">
          13
         </a>
         ]. This concept is supported by the observation that female patients with disorders of hyperandrogenism (eg, polycystic ovarian syndrome, ovarian hyperthecosis, or adrenal or ovarian androgen-secreting tumors) may develop early-onset FPHL as a feature of these diseases [
         <a href="#rid14">
          14
         </a>
         ]. However, androgen levels are normal in most patients with FPHL, indicating that our understanding of the pathogenesis of this disorder remains incomplete [
         <a href="#rid14">
          14,15
         </a>
         ]. In a series of 109 women with moderate to severe FPHL, laboratory evidence for hyperandrogenism was present in only 39 percent [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Proposed theories on the mechanisms through which female patients with normal androgen levels could develop FPHL include increased sensitivity of hair follicles to androgens and an influence of estrogens on the development of this condition [
         <a href="#rid12">
          12,16
         </a>
         ]. The age-related increase in FPHL, with the highest rates in postmenopausal females, suggests the possibility of a role for estrogen. However, studies have demonstrated conflicting evidence on whether estrogens stimulate or inhibit hair growth [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H432607110">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         While it is known that genetic susceptibility influences the development of male androgenetic alopecia, relatively little is known regarding the genetic basis and inheritance pattern of female pattern hair loss [
         <a href="#rid12">
          12
         </a>
         ]. An Australian gene-wide association study of White women suggested that the aromatase gene (
         <em>
          CYP19A1
         </em>
         ) may contribute to FPHL [
         <a href="#rid17">
          17
         </a>
         ]. However, no definitive familial inheritance has been identified. Multiple genes may contribute to susceptibility to FPHL. (See
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H109567558">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FPHL is a nonscarring form of hair loss that presents as a progressive reduction in the density of terminal scalp hairs in a characteristic distribution  (
         <a class="graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195" href="/z/d/graphic/87193.html" rel="external">
          picture 1A-C
         </a>
         ). The frontal scalp and vertex of the scalp are the primary sites of involvement. Although diffuse involvement occasionally occurs, the occipital scalp is usually relatively spared.
        </p>
        <p>
         The exact pattern of hair loss varies among patients with FPHL. In some patients, the frontal scalp thinning is most prominent, resulting in the visualization of a "Christmas tree-like" pattern when the hair is parted at the midline [
         <a href="#rid18">
          18,19
         </a>
         ], whereas in others, diffuse central thinning is the most pronounced feature [
         <a href="#rid20">
          20
         </a>
         ]. The frontal hairline is usually relatively spared, though patients frequently exhibit mild bitemporal thinning [
         <a href="#rid13">
          13,21,22
         </a>
         ]. A combined pattern that resembles male androgenetic alopecia (frontotemporal recession and vertex loss) is infrequently seen [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Scarring, inflammation, and scale are not clinical features of FPHL. If these features are seen in a patient with hair loss, another scalp disorder may be present in conjunction with FPHL or may be solely responsible for the clinical findings. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss"
         </a>
         .)
        </p>
        <p>
         A variety of methods have been used to classify the clinical features of FPHL. The Ludwig scale is one of the most commonly used grading scales  (
         <a class="graphic graphic_figure graphicRef87190" href="/z/d/graphic/87190.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. Other scales that have been used to describe the severity of FPHL include the Sinclair  (
         <a class="graphic graphic_picture graphicRef87210" href="/z/d/graphic/87210.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ] and Savin [
         <a href="#rid18">
          18
         </a>
         ] scales.
        </p>
        <p>
         The FPHL Severity Index, a three-component severity scale, has been proposed as a method to facilitate earlier recognition of FPHL and to assess disease severity over time [
         <a href="#rid23">
          23
         </a>
         ]. The FPHL Severity Index involves assessment of hair shedding, midline hair density, and trichoscopic findings. This scale has not been validated.
        </p>
        <p class="headingAnchor" id="H605925860">
         <span class="h1">
          ASSOCIATED DISORDERS
         </span>
        </p>
        <p class="headingAnchor" id="H352182082">
         <span class="h2">
          Psychosocial dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with FPHL experience negative psychosocial effects related to the condition [
         <a href="#rid24">
          24-26
         </a>
         ]. As an example, in a questionnaire-based study that included 96 women with FPHL and 56 female control subjects, 70 percent of the affected women reported that they were very upset to extremely upset about their hair loss [
         <a href="#rid26">
          26
         </a>
         ]. Women with hair loss experienced more feelings of negative body image, poorer self-esteem, less of a sense of control over their lives, and had a less satisfying quality of life than the control group. A separate study in which 58 women were interviewed about the effects of FPHL on their quality of life also found that hair loss frequently was accompanied by negative psychosocial effects. In this study, 88 percent of women felt that the hair loss negatively influenced daily life [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Adolescent girls with FPHL may also experience psychosocial dysfunction. Girls with FPHL may suffer from poor self-esteem and impaired functioning at home, school, or work and in interpersonal relationships [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         When managing patients with FPHL, clinicians should remain cognizant that the clinical assessment of the severity of FPHL may not be consistent with the patient's perception of the severity of hair loss and the psychosocial impact of the condition. In a questionnaire-based study of 104 women with FPHL, telogen effluvium, or alopecia areata, the patient perception of the severity of hair loss tended to be greater than the perception of the examining dermatologist [
         <a href="#rid28">
          28
         </a>
         ]. In addition, the patients' severity ratings correlated more closely with the effects of hair loss on patient quality of life than the severity ratings given by the dermatologist.
        </p>
        <p class="headingAnchor" id="H432607899">
         <span class="h2">
          Associated medical conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain medical disorders may be associated with FPHL. In addition to causes of hyperandrogenism (eg, ovarian or adrenal tumors, polycystic ovarian syndrome, adrenal hyperplasia), links between FPHL and insulin resistance, hypertension, and increased risk for death from diabetes or heart disease have been reported [
         <a href="#rid29">
          29-31
         </a>
         ]. Further study is necessary to clarify whether the associations between FPHL and these conditions are valid. Of note, cardiovascular risk factors have been associated with androgenetic alopecia in men. (See
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Cardiovascular disease and metabolic syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H109567572">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of female pattern hair loss is usually made clinically. Scalp biopsies are helpful aids for diagnosis when concomitant disorders of the scalp confound the clinical findings or the diagnosis is unclear. Laboratory tests to assess for hyperandrogenism are performed when clinical findings suggestive of hyperandrogenism are present.
        </p>
        <p class="headingAnchor" id="H605925949">
         <span class="h2">
          Patient history
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient history can provide clues to support or negate a diagnosis of FPHL and to identify an underlying hyperandrogenic state. We typically inquire about the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age of onset, duration, and rate of progression of hair loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of signs of virilization (hirsutism, deepening of voice, clitoral enlargement)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gynecologic and obstetrical history (menstrual irregularities, difficulty conceiving)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of other medical disorders, significant changes in health status, medication list
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of hormonal or nutritional supplements that may contain androgens
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of male and female hair loss
        </p>
        <p>
        </p>
        <p>
         A rapid onset of diffuse hair loss may suggest acute telogen effluvium, particularly when the history suggests a change in health status (eg, serious illness, pregnancy, significant weight loss) or medication changes within the preceding several months. Of note, telogen effluvium may coexist with FPHL, and an episode of telogen effluvium may unmask underlying FPHL. The gynecologic history and assessment for signs of virilization help to identify patients for whom an evaluation for hyperandrogenism is indicated. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Patients with FPHL may first notice their hair loss as the progressive thinning of a ponytail or as increasing visibility of the scalp through the hair in the frontal and vertex areas of the scalp. These features are typically noted over the course of months to years. Although the onset and progression of FPHL is often insidious, occasional patients describe noticing specific episodes of increased hair loss prior to a noticeable change in terminal hair density. Patients may also complain of an increased propensity for sunburns on the scalp as hair coverage diminishes.
        </p>
        <p class="headingAnchor" id="H605925941">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A full skin examination that includes evaluation of the scalp, face, body, and nails is advised in patients who present with a new complaint of hair loss. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss", section on 'Physical examination'
         </a>
         .)
        </p>
        <p>
         The examination of the scalp and scalp hair should focus on identifying the distribution of hair loss and the caliber of hairs within the involved areas. Findings consistent with FPHL include the detection of terminal hair loss that is primarily localized to the frontal scalp and/or vertex of the scalp and miniaturized hairs (shorter and thinner hairs or vellus hairs). The use of a sheet of paper as a contrasting background can facilitate visualization of individual hairs.
        </p>
        <p>
         Comparing the part width in the frontal or vertex scalp with the occipital scalp, which is usually relatively spared, provides a visual aid for the assessment of the reduction in hair density. Even in patients who develop diffuse hair loss from FPHL, hair thinning usually remains most prominent in the frontal and vertex areas [
         <a href="#rid13">
          13,32
         </a>
         ].
        </p>
        <p>
         The examination of the scalp should also focus on the detection of clinical features such as inflammation, scarring, or scale. The presence of these features strongly suggests that the hair loss is caused by a different disease or that FPHL coexists with another scalp disorder. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss"
         </a>
         .)
        </p>
        <p>
         The examination of other body sites may result in the identification of features useful for diagnosis and patient management. For example, patients with diffuse alopecia areata may have nail abnormalities and patchy hair loss on other body sites, findings that are not associated with FPHL. In addition, the presence of hirsutism, acne, and obesity suggest the possibility of a hyperandrogenic state related to polycystic ovarian syndrome or another hormonal abnormality. (See
         <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">
          "Alopecia areata: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">
          "Clinical manifestations of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
         Hair pull tests, which can identify increased shedding of telogen hairs, may be positive in early hair loss on the central scalp, but are typically negative in patients with long-standing FPHL [
         <a href="#rid21">
          21
         </a>
         ]. A positive hair pull test suggests the possibility of active telogen effluvium or alopecia areata. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss", section on 'Hair pull test'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H605926128">
         <span class="h3">
          Dermoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermoscopy of the scalp (also known as trichoscopy) may be useful for diagnosis [
         <a href="#rid33">
          33,34
         </a>
         ]. Dermoscopic features of FPHL and male androgenetic alopecia include hair diameter diversity, perifollicular pigmentation/peripilar signs, and yellow dots [
         <a href="#rid34">
          34
         </a>
         ]. Focal atrichia may also be present. (See
         <a class="medical medical_review" href="/z/d/html/13521.html" rel="external">
          "Overview of dermoscopy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H352182242">
         <span class="h2">
          Scalp biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although scalp biopsies usually are not needed to diagnose FPHL, biopsies can be helpful in cases in which the clinical evaluation does not provide a definitive diagnosis. Examples of scenarios in which a biopsy may be particularly useful include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distinguishing FPHL from telogen effluvium or diffuse alopecia areata
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distinguishing FPHL from scarring alopecia when the clinical differentiation between scarring and nonscarring alopecia is difficult
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identifying coexisting scalp disorders
        </p>
        <p>
        </p>
        <p>
         Scalp biopsies should be performed within an affected area and should extend into the subcutaneous fat. It is best to avoid the bitemporal area, since follicular miniaturization in this area is common in individuals without hair loss [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         A 4 mm punch biopsy usually provides sufficient tissue for histologic examination. We typically perform two 4 mm punch biopsies so that one specimen can be processed with vertical sectioning and the other with horizontal sectioning [
         <a href="#rid35">
          35-37
         </a>
         ]. Doing so allows the pathologist to examine the hair follicles in both longitudinal and cross-sections. Many dermatopathologists prefer to receive two specimens. (See
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Histopathology'
         </a>
         .)
        </p>
        <p>
         The typical histopathologic features of FPHL are identical to those of male androgenetic alopecia. They include [
         <a href="#rid7">
          7,38
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">
          "Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Histopathology'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased number of miniaturized hair follicles and reduced size of sebaceous glands
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased anagen to telogen ratio
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased number of follicular stelae
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perifollicular inflammation around the upper portion of the hair follicle with or without perifollicular fibrosis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H432607982">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although no serologic tests provide a definitive diagnosis of FPHL, such tests are helpful for identifying an underlying hyperandrogenic state. Testing for hyperandrogenism is performed in female patients with FPHL when the clinical features suggestive of hyperandrogenism are present (eg, hirsutism, irregular menses, moderate to severe acne, treatment-refractory adult acne, acanthosis nigricans, or galactorrhea). We typically obtain a free and/or total testosterone level and dehydroepiandrosterone sulfate (DHEAS) level as initial screening tests [
         <a href="#rid21">
          21
         </a>
         ]. Hormonal contraceptives should be discontinued for at least two months prior to androgen testing [
         <a href="#rid39">
          39
         </a>
         ]. Additional tests for specific disorders of hyperandrogenism are added as indicated. (See
         <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">
          "Evaluation of premenopausal women with hirsutism", section on 'Biochemical testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432607989">
         <span class="h2">
          Adjunctive tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional procedures that may be utilized for the evaluation and follow-up of FPHL include trichograms and phototrichograms. A trichogram is a technique in which 25 to 50 hairs are grasped with a needle holder and plucked from the scalp followed by an examination of the proximal ends of the hair to assess for the proportion of hairs in telogen. Trichograms are now seldom used in the diagnosis of FPHL. The results of one retrospective study suggest that dermoscopy (trichoscopy) is more useful for the diagnosis of FPHL than trichograms [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="local">
          'Dermoscopy'
         </a>
         above.)
        </p>
        <p>
         Phototrichograms are imaging techniques used to closely examine the features of hair loss for diagnosis and follow-up. A small area of hair is trimmed and followed with imaging for the proportion of regrowing (anagen) hairs, resting (telogen) hairs, and shed hairs, as well as the rate of growth, and hair density [
         <a href="#rid41">
          41
         </a>
         ]. Computerized techniques for performing phototrichograms have been developed (TrichoScan and Folliscope) [
         <a href="#rid42">
          42-46
         </a>
         ]. Phototrichograms are primarily utilized in clinical studies and specialized hair clinics. (See
         <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">
          "Evaluation and diagnosis of hair loss", section on 'Trichograms and phototrichograms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432606918">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple hair and scalp disorders may present with clinical features that resemble FPHL [
         <a href="#rid47">
          47
         </a>
         ]. Careful review of the patient history, physical examination findings, and biopsy (when necessary) is of value for differentiating these disorders from FPHL. Of note, since FPHL is a common condition, the coexistence of FPHL with other disorders must also be considered when patients present with features that are not entirely consistent with FPHL:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Telogen effluvium
         </strong>
         – Telogen effluvium is the disorder that may be most difficult to distinguish from FPHL. Patients present with acute or chronic noninflammatory, diffuse hair loss [
         <a href="#rid48">
          48
         </a>
         ]. The clinical history is often of value for identifying this diagnosis. For example, a major illness, severe psychologic trauma, significant weight loss, childbirth, and certain medications may precipitate an episode of acute telogen effluvium that begins a few months after the insult. In telogen effluvium, hair loss occurs in all areas of the scalp, although the hair loss may be most evident in the temporal area  (
         <a class="graphic graphic_picture graphicRef76636" href="/z/d/graphic/76636.html" rel="external">
          picture 4
         </a>
         ). A hair pull test often demonstrates increased shedding of telogen hairs in patients with active telogen effluvium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diffuse alopecia areata
         </strong>
         – The rare diffuse form of alopecia areata is characterized by diffuse reduction in hair density  (
         <a class="graphic graphic_picture graphicRef87197" href="/z/d/graphic/87197.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid47">
          47
         </a>
         ]. Due to the preferential loss of pigmented hairs, adult patients may complain of rapid graying of the hair. Though not always present, a personal or family history of alopecia areata, the detection of circumscribed areas of complete hair loss, and nail abnormalities offer support to this diagnosis. A biopsy is useful for confirming the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">
          "Alopecia areata: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central centrifugal cicatricial alopecia
         </strong>
         –
         <strong>
         </strong>
         Central centrifugal cicatricial alopecia is a scarring alopecia that most commonly occurs in adult females of African descent [
         <a href="#rid49">
          49
         </a>
         ]. The classic location on the vertex of the scalp contributes to the potential for confusion of this diagnosis with FPHL  (
         <a class="graphic graphic_picture graphicRef87198" href="/z/d/graphic/87198.html" rel="external">
          picture 6
         </a>
         ). The detection of loss of follicular ostia indicates the presence of scarring. Pustules or inflammation may be detected in early disease. Biopsies are used to confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/15681.html" rel="external">
          "Central centrifugal cicatricial alopecia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frontal fibrosing alopecia
         </strong>
         – Frontal fibrosing alopecia is an uncommon scarring alopecia that is usually characterized by frontotemporal recession, perifollicular erythema and follicular hyperkeratosis [
         <a href="#rid50">
          50
         </a>
         ]. Eyebrow loss may also occur. The detection of clinical and histologic signs consistent with a lymphocytic scarring alopecia aid in diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">
          "Lichen planopilaris", section on 'Frontal fibrosing alopecia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Traction alopecia
         </strong>
         –
         <strong>
         </strong>
         Traction alopecia is a form of hair loss that occurs as a result of chronic tension on the hair shaft and follicle  (
         <a class="graphic graphic_picture graphicRef60331" href="/z/d/graphic/60331.html" rel="external">
          picture 7
         </a>
         ). Tight braiding of the hair is a common cause of this condition. Hair loss due to traction alopecia is often located at the hairline. Although the hair loss is reversible initially, hair loss may become permanent if tension on the hair follicles continues. The patient history is useful for diagnosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1329947474">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117218.html" rel="external">
          "Society guideline links: Alopecia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H452176536">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Female pattern hair loss (FPHL) is a common, nonscarring form of hair loss that most commonly occurs in adult females. The highest prevalence of FPHL is found in postmenopausal females. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Although hormonal factors and genetic predisposition are believed to contribute to FPHL, the mechanism through which these factors lead to FPHL is not entirely clear. The majority of female patients with FPHL do not have abnormal levels of serum androgens. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Classically, FPHL presents with a slow, progressive transition of terminal hairs on the frontal scalp and/or vertex of the scalp to shorter, thinner hairs and vellus hairs. The process results in a visible reduction in hair coverage on the scalp  (
         <a class="graphic graphic_picture graphicRef87193 graphicRef87194 graphicRef87195" href="/z/d/graphic/87193.html" rel="external">
          picture 1A-C
         </a>
         ). The occipital scalp and frontal hairline are often relatively spared. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosocial impact
         </strong>
         – Although FPHL does not cause physical discomfort or physical disability, the hair loss can contribute to significant psychologic distress. (See
         <a class="local">
          'Psychosocial dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of FPHL is usually made clinically, based upon the patient history and physical examination. The diagnosis is suggested by the detection of a reduction in hair density in the characteristic distribution and an increased prevalence of miniaturized hairs. Skin biopsies are not usually performed but can be helpful when the diagnosis is uncertain or when a concomitant scalp disorder is suspected. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of FPHL includes several types of nonscarring and scarring hair loss. Telogen effluvium, central centrifugal cicatricial alopecia, and traction alopecia are examples of relatively common disorders that share features with FPHL. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Atanaskova Mesinkovska N, Bergfeld WF. Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 2013; 31:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol 2018; 4:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Hairdressing and the prevalence of scalp disease in African adults. Br J Dermatol 2007; 157:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos PM, Miot HA. Female Pattern Hair Loss: a clinical and pathophysiological review. An Bras Dermatol 2015; 90:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TL, Zhou C, Shen YW, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol 2010; 162:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez ME, Cantatore-Francis J, Orlow SJ. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br J Dermatol 2010; 163:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griggs J, Burroway B, Tosti A. Pediatric androgenetic alopecia: A review. J Am Acad Dermatol 2021; 85:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol 2006; 155:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011; 52:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003; 8:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988; 19:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt JB, Lindmaier A, Trenz A, et al. Hormone studies in females with androgenic hairloss. Gynecol Obstet Invest 1991; 31:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camacho-Martínez FM. Hair loss in women. Semin Cutan Med Surg 2009; 28:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yip L, Zaloumis S, Irwin D, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009; 161:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol 1999; 40:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001; 45:S70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005; 52:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol 1988; 18:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harries M, Tosti A, Bergfeld W, et al. Towards a consensus on how to diagnose and quantify female pattern hair loss - The 'Female Pattern Hair Loss Severity Index (FPHL-SI)'. J Eur Acad Dermatol Venereol 2016; 30:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999; 141:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Der Donk J, Hunfeld JA, Passchier J, et al. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med 1994; 38:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993; 29:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price VH. Androgenetic alopecia in adolescents. Cutis 2003; 71:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66:e97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A, et al. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia. Br J Dermatol 2010; 162:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsso P, Rajala U, Laakso M, et al. Health-related quality of life and physical well-being among a 63-year-old cohort of women with androgenetic alopecia; a Finnish population-based study. Health Qual Life Outcomes 2005; 3:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol 2013; 149:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang H, Kang TW, Lee SD, et al. The changing patterns of hair density and thickness in South Korean women with hair loss: clinical office-based phototrichogram analysis. Int J Dermatol 2009; 48:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Caulloo S, Zhao Y, et al. Female pattern hair loss: clinico-laboratory findings and trichoscopy depending on disease severity. Int J Trichology 2012; 4:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol 2011; 38:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headington JT. Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle. Arch Dermatol 1984; 120:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horenstein MG, Jacob JS. Follicular streamers (stelae) in scarring and non-scarring alopecia. J Cutan Pathol 2008; 35:1115.
          </a>
         </li>
         <li class="breakAll">
          Messenger AG. Androgenetic alopecia. In: Hair Diseases: Medical, Surgical, and Cosmetic Treatments, McMichael AJ, Hordinsky MK (Eds), Informa Healthcare, 2008. p.108.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez LA, Pérez M, Centeno I, et al. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril 2007; 87:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galliker NA, Trüeb RM. Value of trichoscopy versus trichogram for diagnosis of female androgenetic alopecia. Int J Trichology 2012; 4:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhurat R. Phototrichogram. Indian J Dermatol Venereol Leprol 2006; 72:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedel-Baima B, Riedel A. Use of the TrichoScan to assess female pattern hair loss. Dermatol Surg 2009; 35:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BS, Chan JY, Monselise A, et al. Assessment of hair density and caliber in Caucasian and Asian female subjects with female pattern hair loss by using the Folliscope. J Am Acad Dermatol 2012; 66:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Neste D, Trüeb RM. Critical study of hair growth analysis with computer-assisted methods. J Eur Acad Dermatol Venereol 2006; 20:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassmueller J, Rowold E, Frase T, Hughes-Formella B. Validation of TrichoScan technology as a fully-automated tool for evaluation of hair growth parameters. Eur J Dermatol 2009; 19:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraogi PP, Dhurat RS. Automated Digital Image Analysis (TrichoScan®) for Human Hair Growth Analysis: Ease versus Errors. Int J Trichology 2010; 2:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. J Am Acad Dermatol 2002; 47:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002; 27:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summers P, Kyei A, Bergfeld W. Central centrifugal cicatricial alopecia - an approach to diagnosis and management. Int J Dermatol 2011; 50:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol 2012; 67:955.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15679 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23159181" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30627618" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17725667" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hairdressing and the prevalence of scalp disease in African adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26375223" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Female Pattern Hair Loss: a clinical and pathophysiological review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20105167" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of androgenetic alopecia in China: a community-based study in six cities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11231244" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence of female androgenetic alopecia (female pattern alopecia).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20795997" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20346026" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31415838" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pediatric androgenetic alopecia: A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11251562" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hair density, hair diameter and the prevalence of female pattern hair loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17034520" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Follicular miniaturization in female pattern hair loss: clinicopathological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21605090" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12894991" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Androgenetic alopecia in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3192772" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1832134" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hormone studies in females with androgenic hairloss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19341939" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hair loss in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438456" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9922024" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11511856" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Female pattern hair loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/921894" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15692478" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation and treatment of male and female pattern hair loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3385027" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Patterned androgenic alopecia in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26676524" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Towards a consensus on how to diagnose and quantify female pattern hair loss - The 'Female Pattern Hair Loss Severity Index (FPHL-SI)'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583042" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The psychosocial consequences of androgenetic alopecia: a review of the research literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8146707" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8408792" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12635889" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Androgenetic alopecia in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21601948" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906217" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypertension and aldosterone levels in women with early-onset androgenetic alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16120206" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Health-related quality of life and physical well-being among a 63-year-old cohort of women with androgenetic alopecia; a Finnish population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677087" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19126045" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The changing patterns of hair density and thickness in South Korean women with hair loss: clinical office-based phototrichogram analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22628986" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Female pattern hair loss: clinico-laboratory findings and trichoscopy depending on disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21175759" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Trichoscopy for common hair loss diseases: algorithmic method for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8496421" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6703750" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18616766" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Follicular streamers (stelae) in scarring and non-scarring alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18616766" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Follicular streamers (stelae) in scarring and non-scarring alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17118366" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22628985" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Value of trichoscopy versus trichogram for diagnosis of female androgenetic alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16766847" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Phototrichogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19400886" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Use of the TrichoScan to assess female pattern hair loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177643" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Assessment of hair density and caliber in Caucasian and Asian female subjects with female pattern hair loss by using the Folliscope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684287" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Critical study of hair growth analysis with computer-assisted methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19220982" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Validation of TrichoScan technology as a fully-automated tool for evaluation of hair growth parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21188016" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Automated Digital Image Analysis (TrichoScan®) for Human Hair Growth Analysis: Ease versus Errors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12451364" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Approach to the adult female patient with diffuse nonscarring alopecia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12190639" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Telogen effluvium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22097988" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Central centrifugal cicatricial alopecia - an approach to diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503342" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Frontal fibrosing alopecia: a review of 60 cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
